美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Baillie Gifford International Alpha ETF

25.23

+0.01060.04%

成交量：8

成交额：201

市值：3.28亿

市盈率：- -

高：25.23

开：25.22

低：25.23

收：25.22

52周最高：25.97

52周最低：23.97

股本：1,301.20万

流通股本：1,301.20万

量比：0.00

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

诺和诺德回应“司美回流药”：支持并全力配合打击非法行为继续推进授权认证渠道体系

美股异动 | 资本市场日230亿美元目标不及预期诺和诺德(NVO.US)下跌超8%

西门子医疗与诺和诺德宣布合作推进代谢相关脂肪性肝病及代谢相关脂肪性肝炎诊疗。

诺和诺德首席执行官：我不会排除收购已经上市的产品或资产。

诺和诺德首席财务官：合理预期公司到2030年应能实现中个位数的复合年增长率增长

减肥药巨头诺和诺德本轮调整，裁掉了1.3万个岗位

诺和诺德首席财务官：目标是在2030年之前，将营业利润率维持在与当前大致持平的水平。

美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期

美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期

诺和诺德ADR股价跌至盘中低点7.4%。

诺和诺德：墨西哥将成为Wegovy口服药的下一个上市市场。

诺和诺德一年内裁员1.3万人

环球市场播报

诺和诺德美国业务负责人表示，目前Wegovy整体业务中50%的销售以及Wegovy口服药在美国90%的销售来自自费渠道。

诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。

诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。

诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%

华尔街见闻

诺和诺德：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组

诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。

诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。

诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BGIA/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BGIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","market":"US","secType":"STK","nameCN":"Baillie Gifford International Alpha ETF","latestPrice":25.2294,"timestamp":1791921600000,"preClose":25.2188,"halted":0,"volume":8,"delay":0,"changeRate":0.00042032134756596714,"floatShares":13012033,"shares":13012033,"eps":0,"marketStatus":"未开盘","change":0.0106,"latestTime":"10-13 16:00:00 EDT","open":25.2188,"high":25.2294,"low":25.2294,"amount":201,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":25.2188,"bidAskSpread":0,"volumeRatio":0.002641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","floatShares":13012033,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.002641,"shares":13012033,"dividePrice":0,"high":25.2294,"amplitude":0,"preClose":25.2188,"low":25.2294,"week52Low":23.9707,"pbRate":"--","week52High":25.97,"institutionHeld":0,"latestPrice":25.2294,"eps":0,"divideRate":0,"volume":8,"delay":0,"ttmEps":0,"open":25.2188,"prevYearClose":25.2,"prevWeekClose":25.3417,"prevMonthClose":24.9683,"prevQuarterClose":24.9683,"fiveDayClose":25.4651,"twentyDayClose":24.9961,"sixtyDayClose":24.2745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BGIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BGIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BGIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BGIA\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669964190","title":"诺和诺德回应“司美回流药”：支持并全力配合打击非法行为 继续推进授权认证渠道体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2669964190","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669964190?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 11:05","pubTimestamp":1790046311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669641361","title":"美股异动 | 资本市场日230亿美元目标不及预期 诺和诺德(NVO.US)下跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669641361","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669641361?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 23:34","pubTimestamp":1790004845,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，诺和诺德低开低走，截至发稿，下跌超8%。消息面上，9月21日，诺和诺德在伦敦举办“资本市场日”，承诺将在未来几年推出超过五款重磅药物，并实现超过230亿美元的新增销售额。自2025年起，人身伤害律所Weitz & Luxenberg在新泽西州法院代表患者提起90余起NAION索赔诉讼，这些患者在服用司美格鲁肽期间患上NAION，正在向诺和诺德索赔。","market":"fut","thumbnail":"https://static.tigerbbs.com/e03701ee4766df844c287cbe2c6a7e3c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e03701ee4766df844c287cbe2c6a7e3c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499030.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"美股异动 | 资本市场日230亿美元目标不及预期 诺和诺德(NVO.US)下跌超8%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669716192","title":"西门子医疗与诺和诺德宣布合作推进代谢相关脂肪性肝病及代谢相关脂肪性肝炎诊疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669716192","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669716192?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:45","pubTimestamp":1790001933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","BK4543","BK4206","SIEGY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669161801","title":"诺和诺德首席执行官：我不会排除收购已经上市的产品或资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669161801","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669161801?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:27","pubTimestamp":1790000834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169240","title":"诺和诺德首席财务官：合理预期公司到2030年应能实现中个位数的复合年增长率增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169240","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169240?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:13","pubTimestamp":1789999986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669318161","title":"减肥药巨头诺和诺德本轮调整，裁掉了1.3万个岗位","url":"https://stock-news.laohu8.com/highlight/detail?id=2669318161","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669318161?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:08","pubTimestamp":1789999702,"startTime":"0","endTime":"0","summary":"去年9月份宣布要裁员9000人的诺和诺德，于9月21日在伦敦举办的资本市场日上披露了最终减员情况。诺和诺德方面表示，通过本轮组织调整，公司节约成本超100亿（15.35亿美元）丹麦克朗，帮助公司重新投向商业化与研发；过往调整累计涉及约1.3万个岗位，目前全球全职员工为6.6万人。诺和诺德本轮人员优化背后，核心动因是支撑公司七成以上营收的王牌产品司美格鲁肽，正面临增长承压的挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880315953.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880315953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FHLC","IYH","THNR","NVOC","MEDI","NBDS","NVOX","NVOH","FXH","PJP","RSPH","CURE","BGIA","PINK","TRUH","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169498","title":"诺和诺德首席财务官：目标是在2030年之前，将营业利润率维持在与当前大致持平的水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169498","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169498?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669297169","title":"美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669297169","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669297169?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999569,"startTime":"0","endTime":"0","summary":"诺和诺德(NVO.US)盘初大跌超7%。消息面上，诺和诺德上调全年展望，今年销售额和利润的最大降幅可能为6%，此前预测降幅可能高达12%。Q2 Wegovy药片销售额为32.2亿丹麦克朗，低于预期的32.7亿克朗。Wegovy被认为是现代肥胖症药物中最成功的新品之一，市场对其寄予厚望。\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\n            责任编辑：山上","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/09/21220658502008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116946","title":"美股异动丨诺和诺德盘初跌超7%，上调全年展望至降幅6%，Wegovy药片Q2销售不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116946","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669116946?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:06","pubTimestamp":1789999569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669691601","title":"诺和诺德ADR股价跌至盘中低点7.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669691601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669691601?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 22:03","pubTimestamp":1789999394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["DINT","APIE","CVY","AADR","ARMH","DIVL","SAPH","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669816520","title":"诺和诺德：墨西哥将成为Wegovy口服药的下一个上市市场。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669816520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669816520?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:57","pubTimestamp":1789995431,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669165759","title":"诺和诺德一年内裁员1.3万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2669165759","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669165759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:52","pubTimestamp":1789995120,"startTime":"0","endTime":"0","summary":"诺和诺德周一表示，过去一年公司裁员 1.3 万人。在面向投资者的演示材料中，诺和诺德称过去一年又有 4000 人离开公司。投资者期待诺和诺德夺回被礼来抢占的市场份额。近几个月诺和诺德多项临床试验遇挫，其中一款旨在降低心梗风险的药物，近期在三期临床试验宣告失败。不过，诺和诺德在减重口服药领域仍领先礼来，其下一代肥胖药物 CagriSema 预计明年上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-21/doc-inisqzxz5966167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163089","title":"诺和诺德美国业务负责人表示，目前Wegovy整体业务中50%的销售以及Wegovy口服药在美国90%的销售来自自费渠道。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163089?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:24","pubTimestamp":1789993453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163293","title":"诺和诺德美国负责人表示，自一月份以来，诺和诺德在肥胖领域的市场份额大约增加了8个百分点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163293","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163293?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 20:17","pubTimestamp":1789993070,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669716862","title":"诺和诺德首席科学官表示：我们认为新一代GLP-1在疗效、便利性、安全性与耐受性方面或具备差异化优势。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669716862","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669716862?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:30","pubTimestamp":1789990240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669723157","title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669723157","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669723157?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 19:02","pubTimestamp":1789988564,"startTime":"0","endTime":"0","summary":"诺和诺德公布旗下减重药CagriSema最新临床数据：在与礼来替尔泊肽的直接比较中，CagriSema平均减重12.4%，高于替尔泊肽的9.1%；另一项试验中减重达21%。目前该药已提交FDA审批，预计今年第四季度迎来结果。","market":"nz","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3782221","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德再向礼来“宣战”！CagriSema头对头胜过替尔泊肽，减重12.4%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BGIA","NVO","NVOC","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157581","title":"诺和诺德 ：在REDEFINE 9试验中，CagriSema 1.0毫克/1.0毫克组实现体重降幅21.0%，而安慰剂组","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157581?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:27","pubTimestamp":1789986423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669575841","title":"诺和诺德的卡格瑞司玛减重效果优异，减重幅度达 12.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669575841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669575841?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669157322","title":"诺和诺德：卡格列塞玛在多个支持性终点上的改善效果均优于安慰剂。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669157322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669157322?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:25","pubTimestamp":1789986321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715737","title":"诺和诺德的卡格列赛在REIMAGINE 5试验中减重效果优于替尔泊肽。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669715737?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 18:24","pubTimestamp":1789986281,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":199,"code":"91000000","status":"200"}]}}